Kawa Chiu

Kawa Chiu serves as Chief Technical Officer at Abdera Therapeutics. Abdera Therapeutics operates in the research sector with approximately 70.0 employees. The company is headquartered in San Francisco, California. Abdera Therapeutics generates annual revenue of 1300000.0. To date, Abdera Therapeutics has raised 156825390.0 in total funding, with the most recent round being Series B.

Industry & Role Insights

• • MessageCEO tracks 2,961 executives in the research sector.
• • 13,743 executive contacts are available in California.
• • Our database includes 201,469 c suite-level executives.

Rackspace MailGun Outlook Mobile Friendly Google Tag Manager WordPress.org Remote Render

biotechnology research precision oncology radiotherapeutics targeted cancer therapy antibody engineering precision medicine alpha-emitting radionuclide beta-emitting radionuclide radioisotope delivery cancer cell targeting rover platform therapeutic index optimization solid tumors clinical trials systemic toxicities myelosuppression mitigation phase 1 clinical trial dll3 targeting advanced antibody technology linker-chelator technology heavy chain antibodies high affinity antibodies antigen binding domain chelated radioisotope tumor penetration renal protection therapeutic radiation tumor cell destruction imaging isotopes oncology drug development biologics development collaborative drug discovery potent cell killing mechanisms clinical development guidance highly potent therapeutics solid tumor targeting pharmacokinetic properties innovative cancer treatments target engagement measurement dosimetry assessment antibody-based therapies next-generation therapies biopharmaceutical development cancer treatment alternatives high unmet medical need antibody-drug conjugates theranostic agents biopharmaceutical targeted alpha therapies cancer treatment innovative therapies small cell lung cancer large cell neuroendocrine carcinoma advanced cancer drug discovery fast track designation orphan drug designation oncology patient-centered care advanced radiopharmaceuticals therapeutic effect cancer patients healthcare professionals oncology networks novel therapies cancer research biotechnology cancer care patient advocacy therapeutic innovation personalized medicine health care health wellness & fitness hospital & health care

SN

Srikanth Nandiraju Chief Technology Officer at 1Cell.Ai Inc.

SD

Surinnder Dang Chief Business Officer at 1Cell.Ai Inc.

M

Mark Chief Executive Officer at 23Strands

IT

Ilia Tikhomirov Chief Executive Officer at 35Pharma

AD

Alistair Draffan Chief Executive Officer at 360biolabs Pty Ltd

Outreach Guidance — research Sector

Executives like Kawa Chiu in the research sector receive targeted outreach from sales teams, recruiters, and investors. To stand out, personalize your message with industry-specific context and a clear, specific value proposition relevant to their role at Abdera Therapeutics.

How do I reach Kawa Chiu directly?

Kawa Chiu's verified email address is available to MessageCEO Pro subscribers. They currently serve as Chief Technical Officer at Abdera Therapeutics. Access direct contact info to skip gatekeepers and reach the decision maker.

What company does Kawa Chiu work for?

Kawa Chiu is Chief Technical Officer at Abdera Therapeutics, a company in the research sector with 70.0 employees. The company is based in San Francisco, California.

Can I pitch or sell to Kawa Chiu?

As Chief Technical Officer at Abdera Therapeutics, Kawa Chiu is a key decision-maker in the research sector. MessageCEO Pro gives you verified email to reach Kawa Chiu directly — ideal for B2B sales, partnerships, and executive recruiting.

What industry is Kawa Chiu in?

Kawa Chiu works in the research industry as Chief Technical Officer at Abdera Therapeutics. MessageCEO provides verified contact information for executives across all major industries.

Is Kawa Chiu's contact information verified?

Yes. MessageCEO verifies executive contact information through multiple data sources and regular validation checks. Kawa Chiu's profile is kept up-to-date with the latest available information.

Last updated: May 11, 2026